CD30 ligand
AssigneeImmunex Corporation
InventorsRaymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
Life of this patent
Estimating the term…
Abstract
There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
Claims20
An isolated DNA sequence encoding a CD30 ligand (CD30-L) polypeptide, wherein said CD30-L comprises an amino acid sequence selected from the group consisting of amino acids 1-220 of SEQ ID NO:
- 19, amino acids 1-215 of SEQ ID NO:23, amino acids 1-239 of SEQ ID NO:6, aml amino acids 1-234 of SEQ ID NO:8.
An isolated DNA sequence encoding a soluble CD30-L polypeptide capable of binding CD30, wherein said CD30-L comprises an amino acid sequence selected from the group consisting of amino acids 49-220 of SEQ ID NO:
- 19 and amino acids z-215 of SEQ ID NO:23, wherein z is selected from the group consisting of 44, 45, 46, and 47.
An isolated DNA sequence encoding a CD30-L polypeptide capable of binding CD30, wherein said CD30-L comprises an amino acid sequence selected from the group consisting of amino acids x to 239 of SEQ ID NO:6, wherein x is 1-19, and amino acids y to 234 of SEQ ID NO:8, wherein y is 1-19.
A substantially homogeneous, purified, biologically active human or murine CD30-L protein comprising an amino acid sequence selected from the group consisting of amino acids 1-220 of SEQ ID NO:19, amino acids 1-215 of SEQ ID NO:23, amino acids 1-239 of SEQ ID NO:6, and amino acids 1-234 of SEQ ID NO:8.
A substantially homogeneous soluble CD30-L polypeptide, wherein said soluble CD30-L comprises an amino acid sequence selected from the group consisting of amino acids 49-220 of SEQ ID NO:19 and amino acids z-215 of SEQ 1D NO:23, wherein z is selected from the group consisting of 44, 45, 46, and 47.
A substantially homogeneous purified biologically active CD30-L protein capable of binding CD30, wherein said CD30-L is encoded by a DNA sequence that will hybridize to the nucleotide sequence presented in SEQ ID NO:
- 19 or SEQ ID NO:23 under severely stringent conditions and wherein the CD30-L protein is a full-length CD30-L having a molecular weight (as analyzed by SDS-PAGE) of about 40,000 daltons when in glycosylated form, a CD30-L wherein the amino acid sequence is altered to change the pattern of glycosylation, a CD30-L wherein one or more cysteine residues has been either deleted or replaced by another amino acid, or a CD30-L which has been altered to eliminate one or more dibasic cleavage sites.
Dependencies are inferred from the claim text.